Mental Health DailyResearch. Evidence. Perspective.Published research on duloxetine.
A 2026 neuroscience review argues that chemotherapy-induced peripheral neurotoxicity should not be treated as a purely peripheral nerve problem: CIPN affects 70-90% of patients during chemot…
Read articleA 2026 scoping review screened 956 systematic reviews/guidelines and 604 original studies on cancer-survivor neuropathic pain, but only 11 pharmacological, 2 psychological, and 3 exercise st…
Read articleA 2026 UK Biobank MRI preprint involving 71,214 adults found that chronic pain plus current depression had a structural brain profile that was more than chronic pain plus depression pasted t…
Read articleAntibiotics have long been the cornerstone of modern medicine, but their effectiveness is increasingly threatened by the rise of antibiotic resistance. While the overuse of antibiotics is a …
Read articleIt appears as though the pharmaceutical juggernaut Eli Lilly is facing major legal backlash for failure to disclose discontinuation effects associated with their medication Cymbalta (Duloxet…
Read articleCymbalta (Duloxetine) is a drug that us utilized primarily to treat major depression. It was approved in 2004 by the FDA as an SNRI antidepressant, and would later receive approval for the t…
Read articleCymbalta (Duloxetine) was officially approved by the FDA in 2004 as a new treatment for major depression. It is classified as an SNRI antidepressant which means it inhibits the reuptake of s…
Read article
